Researchers tied Alzheimer’s-associated tau to a specific mitochondrial failure pathway, offering a more direct mechanistic target for tauopathy drug discovery. A Stanford study described how chemically modified tau can enter mitochondria and interfere with energy production, triggering reverse electron transport and downstream stress and inflammation. In preclinical models, blocking the reverse electron transport event alleviated harmful cellular effects and improved cognition-related outcomes in animal studies. The work also included analysis of human cells and patient brain tissue, aimed at mapping the same pathway in clinically relevant systems. The results add to tau’s growing positioning as a drug target beyond aggregation and microtubule disruption, while also suggesting new therapeutic leverage points tied to electron transport chain behavior.